A Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab in Patients With Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin is a PHASE1 clinical asset sponsored by National Cancer Centre, Singapore in Epithelial Ovarian Cancer. SEO and diligence focus: Oregovomab, Nivolumab, Chemotherapy, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.